Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims.

What Is Claimed Is:

1-10. (Canceled).

- 11. (Currently Amended) A polypeptide comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:
- (a) a full length polypeptide of SEQ ID NO: 408 or a full length polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No:Z-ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408 as referenced in Table 1A;
- (b) a secreted form of SEQ ID NO: 408 or a secreted form of the polypeptide encoded by the <u>HACCI17</u> cDNA Clone ID in ATCC Deposit No:Z-ATCC Deposit No. 203071 corresponding to <u>SEQ ID NO: 408 SEQ ID NO:Y as referenced in Table 1A;</u>
- (c) a polypeptide fragment of <u>at least 30 amino acids of SEQ ID NO:Y SEQ ID NO: 408</u> or a polypeptide fragment <u>of at least 30 amino acids encoded</u> by the <u>HACCI17</u> cDNA Clone ID in <u>ATCC Deposit No:Z ATCC Deposit No. 203071</u> corresponding to <u>SEQ ID NO: 408, SEQ ID NO:Y as referenced in Table 1A wherein said fragment has biological activity;</u>
- (d) a polypeptide fragment of <u>at least 50 amino acids of SEQ ID NO:Y-SEQ ID NO: 408</u> or a polypeptide fragment <u>of at least 50 amino acids encoded</u> by the <u>HACCI17 cDNA Clone ID in ATCC Deposit No:Z-ATCC Deposit No. 203071 corresponding to SEQ ID NO:Y SEQ ID NO: 408 as referenced in Table 1A, wherein said fragment has biological activity;</u>
 - (e) a polypeptide domain of SEQ ID NO: Y as referenced in Table 1B;
 - (f) a polypeptide domain of SEQ ID NO: Y as referenced in Table 2; and
 - (g) a predicted epitope of SEQ ID NO:Y as referenced in Table 1B.
 - (e) a polypeptide comprising amino acids 1-218 of SEQ ID NO: 408;
 - (f) a polypeptide comprising amino acids 25-218 of SEQ ID NO: 408; and
 - (g) a polypeptide comprising the mature form of HACCI17 polypeptide encoded by the HACCI17 cDNA in ATCC Deposit No. 203071.
- 12. (Previously Presented) The polypeptide of claim 11, wherein said polypeptide comprises a heterologous amino acid sequence.

13. (Previously Presented) The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

14-15. (Canceled).

- 16. (Currently Amended) A method of making an isolated polypeptide An isolated polypeptide produced by a method comprising:
- (a) culturing the recombinant host cell of claim 15 under conditions such that said polypeptide is expressed expressing the polypeptide of claim 11 by a cell; and
 - (b) recovering said polypeptide.

17-19. (Canceled).

- 20. (Previously Presented) A method of diagnosing diabetes or conditions related to diabetes, or diagnosing susceptibility to diabetes or conditions related to diabetes in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing diabetes or conditions related to diabetes or the susceptibility to diabetes or conditions related to diabetes based on the presence or amount of expression of the polypeptide.
- 21. (Currently Amended) A method for identifying a binding partner to the polypeptide of claim 11 comprising:
 - (a) contacting the polypeptide of claim <u>1143</u> with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.

22-23. (Canceled)

- 24. (Currently Amended) The product produced by the method of claim 2120.
- 25. (New) A polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a full length polypeptide of SEQ ID NO: 408 or a full length polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408;
- (b) a secreted form of SEQ ID NO: 408 or a secreted form of the polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408;
- (c) a polypeptide fragment of at least 30 amino acids of SEQ ID NO: 408 or a polypeptide fragment of at least 30 amino acids encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment has biological activity;
- (d) a polypeptide fragment of at least 50 amino acids of SEQ ID NO: 408 or a polypeptide fragment of at least 50 amino acids encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment has biological activity;
 - (e) a polypeptide comprising amino acids 1-218 of SEQ ID NO: 408;
 - (f) a polypeptide comprising amino acids 25-218 of SEQ ID NO: 408; and
- (g) a polypeptide comprising the mature form of HACCI17 polypeptide encoded by the HACCI17 cDNA in ATTC Deposit No. 203071.
- 26. (New) The polypeptide of claim 25, wherein said polypeptide comprises a heterologous amino acid sequence.
 - 27. (New) The polypeptide of claim 11, wherein said polypeptide is glycosylated.
 - 28. (New) The polypeptide of claim 25, wherein said polypeptide is glycosylated.
 - 29. (New) An isolated polypeptide produced by the method comprising:
 - (a) expressing the polypeptide of claim 25 by a cell; and
 - (b) recovering said polypeptide.
- 30. (New) A method of diagnosing diabetes or conditions related to diabetes, or diagnosing susceptibility to diabetes or conditions related to diabetes in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 25 in a biological sample; and
- (b) diagnosing diabetes or conditions related to diabetes or the susceptibility to diabetes or conditions related to diabetes based on the presence or amount of expression of the polypeptide.
- 31. (New) A method for identifying a binding partner to the polypeptide of claim 25 comprising:
 - (a) contacting the polypeptide of claim 25 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.
 - 32. (New) The product produced by the method of claim 31.